Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Sören Lehmann"'
Autor:
Nona Struyf, Albin Österroos, Mattias Vesterlund, Cornelia Arnroth, Tojo James, Stephanie Sunandar, Georgios Mermelekas, Anna Bohlin, Kerstin Hamberg Levedahl, Sofia Bengtzén, Rozbeh Jafari, Lukas M. Orre, Janne Lehtiö, Sören Lehmann, Päivi Östling, Olli Kallioniemi, Brinton Seashore-Ludlow, Tom Erkers
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-7 (2024)
Abstract Consistent handling of samples is crucial for achieving reproducible molecular and functional testing results in translational research. Here, we used 229 acute myeloid leukemia (AML) patient samples to assess the impact of sample handling o
Externí odkaz:
https://doaj.org/article/b137e1c0bbc24a2a9826fbbf5bd104d4
Autor:
Quang Thinh Trac, Yudi Pawitan, Tian Mou, Tom Erkers, Päivi Östling, Anna Bohlin, Albin Österroos, Mattias Vesterlund, Rozbeh Jafari, Ioannis Siavelis, Helena Bäckvall, Santeri Kiviluoto, Lukas M. Orre, Mattias Rantalainen, Janne Lehtiö, Sören Lehmann, Olli Kallioniemi, Trung Nghia Vu
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Despite some encouraging successes, predicting the therapy response of acute myeloid leukemia (AML) patients remains highly challenging due to tumor heterogeneity. Here we aim to develop and validate MDREAM, a robust ensemble-based predictio
Externí odkaz:
https://doaj.org/article/708587f7449c4c56ba44998f3046d58f
Autor:
Gunnar Juliusson, Christer Nilsson, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Linda Fogelstrand, Panagiotis Baliakas, Tatjana Pandzic, Lucia Cavelier, Anna Eriksson, Albin Österroos, Anna Thunström, Benedicte Piauger, Bertil Uggla, Emma Ölander, Gustav Orrsjö, Jörg Cammenga, Kristina Myhr-Eriksson, Petter Willner Hjelm, Stefan Deneberg, Thoas Fioretos, Martin Höglund, Vladimir Lazarevic
Publikováno v:
HemaSphere, Vol 7, p e38749b6 (2023)
Externí odkaz:
https://doaj.org/article/32aa3e03ec294219906a1419015ccc1c
Autor:
Bianca Tesi, Anna Eriksson, Berivan Baskin, Vladimir Lazarevic, Stefan Deneberg, Martin Höglund, Linda Fogelstrand, Johanna Ungerstedt, Tatjana Pandzic, Magnus Tobiasson, Hege Gravdahl Garelius, Ekaterina Kuchinskaya, Fredrik Persson, Helena Ågerstam, Bertil Uggla, Helene Hallböök, Thoas Fioretos, Ann-Charlotte Thuresson, Sören Lehmann, Claes Ladenvall, Gisela Barbany, Lovisa Vennström, Elisabeth Ejerblad, Lucia Cavelier, Jörg Cammenga, Martin Jädersten, Eva Hellström Lindberg, Panagiotis Baliakas
Publikováno v:
HemaSphere, Vol 7, p e790629d (2023)
Externí odkaz:
https://doaj.org/article/f209dfa4a99d4653aded3f56d2a1befe
Autor:
Lei Chen, Anna Eriksson, Simone Weström, Tatjana Pandzic, Sören Lehmann, Lucia Cavelier, Ulf Landegren
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Rare tumour specific mutations in patient samples act as markers to monitor the course of disease. Here the authors report superRCA assays for rapid, highly specific detection of DNA sequence variants present at very low frequencies in DNA samples wi
Externí odkaz:
https://doaj.org/article/ab9eb478024046d489f6446d4f5b0202
Autor:
Christer Nilsson, Fredrika Linde, Erik Hulegårdh, Hege Garelius, Vladimir Lazarevic, Petar Antunovic, Jörg Cammenga, Stefan Deneberg, Anna Eriksson, Martin Jädersten, Cecilia Kämpe Björkvall, Lars Möllgård, Lovisa Wennström, Emma Ölander, Martin Höglund, Gunnar Juliusson, Sören Lehmann
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic implications in all t-AML patients diag
Externí odkaz:
https://doaj.org/article/f65464ab1d8c4e48807a6b185d655723
Autor:
Lucas C. M. Arruda, Arwen Stikvoort, Melanie Lambert, Liqing Jin, Laura Sanchez Rivera, Renato M. P. Alves, Tales Rocha de Moura, Carsten Mim, Sören Lehmann, Rebecca Axelsson-Robertson, John E. Dick, Jonas Mattsson, Björn Önfelt, Mattias Carlsten, Michael Uhlin
Publikováno v:
Haematologica, Vol 107, Iss 8 (2022)
Less than a third of patients with acute myeloid leukemia (AML) are cured by chemotherapy and/or hematopoietic stem cell transplantation, highlighting the need to develop more efficient drugs. The low efficacy of standard treatments is associated wit
Externí odkaz:
https://doaj.org/article/1561e483da024aaca91e6f7fc419b92b
Autor:
Albin Österroos, Tânia Maia, Anna Eriksson, Martin Jädersten, Vladimir Lazarevic, Lovisa Wennström, Petar Antunovic, Jörg Cammenga, Stefan Deneberg, Fryderyk Lorenz, Lars Möllgård, Bertil Uggla, Emma Ölander, Eliana Aguiar, Fernanda Trigo, Martin Höglund, Gunnar Juliusson, Sören Lehmann
Publikováno v:
Haematologica, Vol 107, Iss 7 (2022)
With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, patients with high-risk of ED must be identified. Our aim wa
Externí odkaz:
https://doaj.org/article/34cdf435ea0a47ee95c6601eadd0be27
Autor:
Simon Hultmark, Aurélie Baudet, Ludwig Schmiderer, Pavan Prabhala, Sara Palma-Tortosa, Carl Sandén, Thoas Fioretos, Rajkumar Sasidharan, Christer Larsson, Sören Lehmann, Gunnar Juliusson, Fredrik Ek, Mattias Magnusson
Publikováno v:
Haematologica, Vol 106, Iss 10 (2020)
Combination treatment has proven effective for patients with acute promyelocytic leukemia, exemplifying the importance of therapy targeting multiple components of oncogenic regulation for a successful outcome. However, recent studies have shown that
Externí odkaz:
https://doaj.org/article/eb07afe4d0a343629492a6a4e40ce48b
Autor:
Sean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, Cynthia BJ Paulin, Lakshmi Sandhow, Juliane Kutzner, Ida Hed Myrberg, Sarah S Bunten, Hanna Axelsson, Si Min Zhang, Azita Rasti, Petri Mäkelä, Si'Ana A Coggins, Sijia Tao, Sharda Suman, Rui M Branca, Georgios Mermelekas, Elisée Wiita, Sun Lee, Julian Walfridsson, Raymond F Schinazi, Baek Kim, Janne Lehtiö, Georgios Z Rassidakis, Katja Pokrovskaja Tamm, Ulrika Warpman‐Berglund, Mats Heyman, Dan Grandér, Sören Lehmann, Thomas Lundbäck, Hong Qian, Jan‐Inge Henter, Torsten Schaller, Thomas Helleday, Nikolas Herold
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 3, Pp n/a-n/a (2020)
Abstract The deoxycytidine analogue cytarabine (ara‐C) remains the backbone treatment of acute myeloid leukaemia (AML) as well as other haematological and lymphoid malignancies, but must be combined with other chemotherapeutics to achieve cure. Yet
Externí odkaz:
https://doaj.org/article/ee94cd1a0d794c99b66c9335300d2f1e